Cancer Research and Treatment10.4143/crt.2018.59820195141527-1539BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 TherapySung-Bae Kim, In-Gu Do, Janice Tsang, Tae-You Kim, Yoon-Sim Yap, Gerardo Cornelio, Gyungyub Gong, Soonmyung Paik, Suee Lee, Ting-Ying Ng, Sarah Park, Ho-Suk Oh, Joanne Chiu, Joohyuk Sohn, Moonhee Lee, Young-Jin Choi, Eun Mi Lee, Kyong-Hwa Park, Christos Nathaniel, Jungsil Ro,,
AboutOpen10.19156/abtpn.2018.0067201841162-165Response to Lapatinib-Capecitabine combination in a young patient with recurrent HER2-positive breast cancer refractory to two lines of therapy with anti-HER2 drugsClementina Savastano, Fortuna Lombardi,
10.21203/ Does Definitive Local Therapy Offer Cure in Select HER2+ De Novo Metastatic Breast Cancer Patients Treated with Dual Anti-HER2 Blockade?Luderve Rosier, Youth Wang, Jihyun Lee, Karen Daily,
Breast Cancer10.1007/s12282-013-0475-12013222192-200Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical studyHiroji Iwata, Hirofumi Fujii, Norikazu Masuda, Hirofumi Mukai, Yuichiro Nishimura, Koichi Katsura, Catherine E. Ellis, Robert C. Gagnon, Seigo Nakamura,,
Breast Cancer: Targets and Therapy10.2147/bctt.s29996201235Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancerSara Hurvitz, Kakkar
European Journal of Cancer10.1016/s0959-8049(17)30213-7201772S40Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cellsC.M. Kurbacher, C. Eichler, A.B. Quade, G. Kunstmann, S. Herz, J.A. Kurbacher, M.R. Warm,
The Breast10.1016/s0960-9776(17)30336-3201732S105Tumor-infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or the combination: a meta-analysis of published randomized clinical trials,
Molecular Therapy10.1016/s1525-0016(16)35998-6201220S77194. Combining the Dual Tyrosine Kinase Inhibitor, Lapatinib, with HER2 Specific Cytotoxic T-Lymphocytes in the Treatment of HER2 Overexpressing Breast Cancer,
Breast Cancer: Targets and Therapy10.2147/bctt.s121502011139Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancerBill Sikov, Merriam
Cancer10.1002/cncr.261012011117215013-5020Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapyAllan Lipton, Kim Leitzel, Suhail M. Ali, Walter Carney, Greg Platek, Klaudia Steplewski, Ron Westlund, Robert Gagnon, Anne-Marie Martin, Julie Maltzman,